Paraquat antidote
Through the combined application of choline materials and glucosamine, the small intestine absorption of paraquat and the induction of P-glycoprotein expression in the lungs has been solved, and the survival of poisoned rats has been significantly improved. , providing an efficient detoxification strategy.
Patent Information
- Application Number
- CN202411030142.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-15
AI Technical Summary
The lack of effective strategies for the treatment of paraquat poisoning leads to high mortality, mainly due to its difficulty in effectively inhibiting absorption and accumulation in the small intestine and lungs. The failure of the prior art to identify major transporters has hindered the development of competitive inhibitors.
Using the combined application of choline materials and glucosamine, choline competitively inhibits the small intestinal transporter activity of paraquat, glucosamine induces the expression of P-glycoprotein in the lungs, promotes the pumping of paraquat from lung cells, and uses it in combination with Reduce toxicity.
The survival rate of rats with acute paraquat poisoning was significantly improved, from 0% to 80%, and an effective detoxification solution was provided by reducing the concentration of blood and lung paraquat and reducing the toxicity.
Smart Images

Figure CN118948818A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of paraquat detoxification and relates to a paraquat detoxifier. Background Art
[0002] Paraquat (1,1'-dimethyl-4,4'-bipyridyl, PQ) is a highly effective herbicide that is widely used worldwide for chemical control of invasive plants. It is worth noting that paraquat is extremely toxic and lethal to humans, especially when ingested accidentally or intentionally, with an annual incidence of more than 3.8 cases per 100,000 people. Despite being banned or restricted in many regions, paraquat is still abused due to adulteration or mislabeling, putting a large number of people at risk of poisoning. Oral ingestion is the main route of paraquat poisoning, which manifests as acute lung and kidney damage, often progressing to pulmonary fibrosis, multiple organ failure and acute respiratory distress syndrome. The clinical treatment of paraquat poisoning focuses mainly on supportive rather than curative measures, usually including comprehensive measures such as gastrointestinal decontamination, blood purification and symptomatic treatment. Due to its extremely strong toxicity and lack of specific treatment drugs, the mortality rate of paraquat poisoning is usually more than 70%.
[0003] Patient survival is strongly inversely related to the amount of paraquat ingested. Therefore, early intervention to prevent oral absorption can significantly reduce toxicity. Standard clinical gastrointestinal decontamination methods have little effect on improving patient survival, mainly because paraquat residues are inevitably absorbed into the blood or the critical window for early intervention within a few hours is missed. Carrier-mediated uptake is the main way for paraquat to enter cells, which suggests that targeted inhibition of transporter activity is a viable strategy. Blocking the binding site of transporters or downregulating the expression of transporters through competitive or non-competitive inhibition is the main method to inhibit transporter activity. Competitive inhibition has attracted attention due to its rapid action, high specificity and reversibility, and has been widely used in drug design and development. However, the main transporter that facilitates paraquat entry into intestinal epithelial cells has not yet been identified, which seriously hinders the development of competitive inhibitors.
[0004] In addition, after inhibiting oral absorption, pulmonary fibrosis caused by lung damage due to the accumulation of paraquat in the lungs is also the main cause of paraquat-related death. P-glycoprotein (P-gp) is a transmembrane transporter protein whose function is to pump substrates from cells to the outside of cells, thereby protecting cells from damage by drugs and toxins. Therefore, inducing or stimulating P-glycoprotein to improve its transport efficiency, pumping paraquat taken up by the lungs from cells to the outside of cells, reducing its relative concentration in the lungs, reducing lung damage, and delaying or even preventing the progression of pulmonary fibrosis is also one of the feasible strategies.
[0005] Therefore, the detoxification strategy of paraquat is to first reduce its oral absorption by competitively inhibiting the activity of paraquat small intestinal transporters, and then use the activation of P-glycoprotein to reduce the accumulation of paraquat in the lungs, thereby reducing its toxicity to achieve the purpose of detoxification. Summary of the invention
[0006] In view of this, one of the objects of the present invention is to provide the use of choline materials and glucosamine in the preparation of paraquat antidote; the second object of the present invention is to provide a paraquat antidote.
[0007] In order to achieve the above object, the present invention provides the following technical solutions:
[0008] 1. Use of choline materials and glucosamine in the preparation of paraquat antidote, wherein the choline material is choline or a pharmaceutically acceptable salt of choline.
[0009] Preferably, in the application, the choline material is first delivered to the person to be detoxified, and then glucosamine is delivered to the person to be detoxified as soon as possible within 24 hours.
[0010] Preferably, the delivery method is any one of oral administration, nasal drops or aerosol inhalation.
[0011] Further preferably, the pharmaceutically acceptable salt of choline to be detoxified is any one or more of choline chloride, choline bitartrate, choline bicarbonate, choline hydrochloride or choline sulfate in rats.
[0012] Preferably, in the application, the mass ratio of the choline material to the substance to be detoxified is 400-600:1, mg:kg;
[0013] The mass ratio of the glucosamine to the substance to be detoxified is 40-60:1, mg:kg.
[0014] 2. A paraquat antidote, comprising choline materials and glucosamine;
[0015] The choline material is choline or a pharmaceutically acceptable salt of choline.
[0016] Preferably, the pharmaceutically acceptable salt of choline is any one or more of choline chloride, choline bitartrate, choline bicarbonate, choline hydrochloride or choline sulfate.
[0017] The beneficial effects of the present invention are:
[0018] 1. The present invention discloses the use of choline materials and glucosamine in the preparation of paraquat antidotes. In the application of the present invention, the choline materials can competitively inhibit the small intestinal transporter activity of paraquat, effectively inhibit the absorption of paraquat in the small intestine, thereby reducing the concentration of paraquat in the blood and reducing its toxicity, and improving the survival rate of acutely poisoned rats from 0% to 50%; in the application of the present invention, glucosamine upregulates the expression of P-glycoprotein in the lungs of rats, promotes the pumping out of paraquat from lung cells, reduces the concentration of paraquat aggregation in the lungs, and improves the survival rate of acutely poisoned rats from 0% to 40%.
[0019] 2. The present invention also discloses a paraquat antidote, which contains choline materials (choline or pharmaceutically acceptable salts of choline) and glucosamine. The combination of the two components increases the survival rate of rats with acute paraquat poisoning from 0% to 80%, and is expected to be used in the detoxification of paraquat poisoning in humans.
[0020] Other advantages, objectives and features of the present invention will be described in the following description to some extent, and to some extent, will be obvious to those skilled in the art based on the following examination and study, or can be taught from the practice of the present invention. The objectives and other advantages of the present invention can be realized and obtained through the following description. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention will be described in detail below in conjunction with the accompanying drawings, wherein:
[0022] Figure 1 is the permeability coefficient of 10 different inhibitors to paraquat eff Effects (n=6 parallel experiments in each group, NS means no significant difference, *p<0.05, **p<0.01);
[0023] Figure 2 The effects of different doses of choline on the pharmacokinetics and bioavailability of paraquat (n=6 parallel experiments in each group, NS indicates no significant difference, *p<0.05, **p<0.01), where a is the blood concentration-time curve, and b is the area under the curve;
[0024] Figure 3 The effect of choline on the pharmacokinetics and bioavailability of paraquat at different administration times (n=6 parallel experiments in each group, NS means no significant difference, **p<0.01), where a is the blood concentration-time curve, and b is the area under the curve;
[0025] Figure 4The effect of choline on the paraquat level accumulated in various organs (n=6 parallel experiments in each group, NS indicates no significant difference, *p<0.05, **p<0.01, ***p<0.005, ****p<0.001), where a is the difference in paraquat lung accumulation level at 2h, and b is the difference in paraquat lung accumulation level at 24h;
[0026] Figure 5 The effects of different doses and administration times of glucosamine on the level of P-glycoprotein in rat lungs (n=3 parallel experiments in each group);
[0027] Figure 6 is the difference in the lung accumulation level of paraquat at different times (n=6);
[0028] Figure 7 The effect of different doses of glucosamine administered five times at intervals of 12 hours on the accumulation of paraquat in the lungs of rats (n=6 parallel experiments in each group, NS means no significant difference, *p<0.05);
[0029] Figure 8 The effect of combined and separate administration of choline and glucosamine on the survival rate of rats with acute paraquat poisoning (n=10);
[0030] Fig. 9 The results of H&E sections of rat lungs after combined administration of choline and glucosamine (n=6). DETAILED DESCRIPTION
[0031] The following describes the embodiments of the present invention by specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that the illustrations provided in the following embodiments only illustrate the basic concept of the present invention in a schematic manner, and the following embodiments and features in the embodiments can be combined with each other without conflict.
[0032] Example 1
[0033] 1. Investigate the effect of choline in inhibiting the absorption of paraquat in the small intestine:
[0034] For the first time, surface plasmon resonance imaging was used to capture the target transporters of paraquat, organic cation transporter 1 (OCT1), organic cation transporter 3 (OCT3), and organic carnitine transporter 2 (OCTN2) in human colon cancer cells (Caco-2), and the accuracy of the results was further verified by cell thermal stability transfer assay-molecular imprinting technology. Then, 10 substrates with high binding scores to the above three transporters were obtained through virtual screening of the ZINC database, and further screening was performed through in vivo intestinal one-way perfusion experiments, and choline was finally determined to be a highly efficient competitive inhibitor. After that, the effects of choline on the pharmacokinetics and tissue distribution of paraquat were further investigated. The experimental process and results of choline inhibiting the absorption of paraquat in the small intestine are as follows:
[0035] 1. Paraquat dosage screening: 30 SD rats aged 8 to 10 weeks and weighing 200±50 g were selected and randomly divided into 6 groups (5 rats in each group). They were gavaged with 50, 100, 150, 250, 300 and 350 mg / kg paraquat, respectively. The mortality of rats within 15 days of paraquat gavage was recorded (the average mortality rate and average survival time of 5 rats in each group were calculated). The results are shown in Table 1.
[0036] Table 1 Effects of different oral doses of paraquat on the mortality of rats
[0037]
[0038] As can be seen from the results in Table 1, when the paraquat gavage does not exceed 100 mg / kg, the paraquat gavage did not cause the death of rats within 15 days, indicating that the paraquat gavage dose ≤ 100 mg / Kg did not show obvious strong toxicity and was not suitable for selection as the attack dose. When the paraquat gavage dose was 150 mg / kg and 250 mg / kg, the rats died obviously, with mortality rates of 16.67% and 33.33%, respectively. Among them, the paraquat gavage dose of 250 mg / kg was selected for the normal attack dose because of its high concentration to meet the needs of analytical instrument detection and long survival time. When the paraquat gavage dose was 300 mg / kg and 350 mg / kg, the rat mortality rate was 100%, which is suitable for the survival rate study of rats with acute paraquat poisoning at high doses. Here, 350 mg / kg is determined as the attack dose for survival rate study.
[0039] 2. Screening the best inhibitor by in vivo intestinal unidirectional perfusion method: SD rats aged 8 to 10 weeks and weighing 200 ± 50 g were selected for the experiment. They were fasted for 24 hours before the experiment. After anesthesia, they were fixed on the operating table, the abdominal cavity was opened along the midline of the abdominal cavity, and a jejunal segment of about 10 cm was selected. T-shaped incisions were made at both ends of the jejunal segment, and saline preheated to 37°C was sucked to gently rinse the intestinal contents, then the cannula was intubated and ligated. The wound was covered with gauze soaked in saline to keep it moisturized and irradiated with infrared light to keep warm. After perfusion with perfusion fluid preheated to 37°C at a flow rate of 1 mL / min for 10 minutes, the flow rate was reduced to 0.2 mL / min, and the timing was started after perfusion equilibrium for 20 minutes. The inlet bottle is filled with perfusion fluid, which is the inflow perfusion fluid; the outlet bottle is used to collect the outflow perfusion fluid. The inlet and outlet bottles are weighed in advance, and 9 mL is accurately sucked into the inlet bottle with a pipette, and the inlet and outlet bottles are replaced every 30 minutes. The outflow perfusate was collected for 3 time periods, and the experiment lasted for 120 minutes. The outflow perfusate was centrifuged at 12000r / min for 10 minutes, and the supernatant was taken and filtered through a 0.45μm microporous filter membrane for quantification by high performance liquid chromatography. After the experiment, the rats were killed, the intestinal segments under investigation were cut off, and the length (L) and circumference of different intestinal segments were measured. The average radius (R) was obtained from the circumference measurements of 3 times.
[0040] The volume and density of the inflowing and outflowing perfusates were corrected by the weight method to eliminate the influence of the volume and density changes of the perfusate on the experimental results. Accurately draw 1.0 mL of the inflowing perfusate, place it in an EP tube of known mass, weigh the liquid mass, and calculate the density of the inflowing perfusate ρ in ; Accurately draw 1.0 mL of outflow perfusate, place it in an EP tube of known mass, weigh the liquid mass, and calculate the density ρ of the outflow perfusate out . Calculate the intestinal absorption parameters absorption rate constant (K) according to the following formulas ① and ② respectively. a ) and apparent permeability coefficient (P eff ) was used to analyze the intestinal absorption of paraquat in rats under different inhibitors.
[0041] ①
[0042] ② ③
[0043] Where V in 、V out are the inflow perfusate volume and outflow perfusate volume (mL), respectively; M in 、M out are the mass of the inflow perfusate and the mass of the outflow perfusate (g), respectively; C in , C outare the concentrations of each component in the inflow perfusate and the concentrations of each component in the outflow perfusate (μg / mL), respectively; R and L are the radius and length (cm) of the intestinal segment under investigation; Q is the perfusion rate, which is set to 0.2 mL / min, but due to the difference in actual perfusion rates, Q = V in / T calculation, the experimental results are shown in Table 2 and Figure 1 shown.
[0044] Table 2 Absorption parameters of paraquat in jejunum under different inhibitors (x±s, n=6)
[0045]
[0046]
[0047] The results in Table 2 show that the apparent permeability coefficient of paraquat without inhibitor is 5.647±3.05310 -4 cm / min, the apparent permeability coefficient of paraquat under choline intervention was 1.390±0.78910 -4 cm / min, which is 4.06 times lower than that of paraquat. This shows that choline can effectively inhibit the jejunal absorption of paraquat and show better inhibitory effect than other inhibitors. As an important nutrient and dietary supplement, choline has an oral median lethal dose of 3400 mg / kg in rats, indicating that it has low toxicity, so it was selected as a highly effective competitive inhibitor.
[0048] Figure 1 is the permeability coefficient of paraquat to 10 different inhibitors P eff (n=6 parallel experiments in each group, NS means no significant difference, *p<0.05, **p<0.01). Figure 1 The results showed that tetraethylammonium chloride (Teac) could reduce the permeability coefficient of paraquat in the jejunum. eff , with significant difference (**p<0.01); choline and ethanolamine (Dea) can also reduce P eff , indicating that choline and ethanolamine (Dea) are both highly effective inhibitors of paraquat absorption after oral administration. Among them, it is worth noting that some inhibitors even increased the permeability coefficient of paraquat, which may be caused by intestinal damage caused by these compounds or other physiological factors, indicating that the intestinal absorption of paraquat is easily affected by other drugs.
[0049] 3. Pharmacokinetic screening of oral dose and time of choline: SD rats aged 8 to 10 weeks and weighing 200 ± 50 g, which had fasted for 24 hours before the experiment, were selected. Paraquat was first gavaged at a dose of 250 mg / kg. After gavage, choline was gavaged at doses of 20, 100 and 500 mg / kg, respectively, with 6 parallel experiments in each group. At 10, 30, 60, 90, 150, 180, 360 and 720 minutes after gavage of choline, about 0.5 mL of blood was collected from the orbital vein of the rat and placed in a centrifuge tube moistened and dried with saturated sodium heparin as a sample. After the sample was allowed to stand for 30 minutes, it was centrifuged at 8000 rpm for 5 minutes to obtain plasma. Subsequently, 200 μL of plasma was taken, 100 μL of 8% perchloric acid solution was added to precipitate protein, vortexed for 30 seconds, and centrifuged at 8000 rpm for 10 minutes to obtain the supernatant. The supernatant was filtered through a 0.4 μm PES membrane and stored in a sample bottle for HPLC analysis. After the optimal dose of choline was determined to be 500 mg / kg, the effects of administration 30 min in advance, at the same time, and 30 min later on the pharmacokinetics of paraquat were investigated. The sample pretreatment was the same as above. The experimental results are shown in Tables 3, 4, Figure 2 and Figure 3 shown.
[0050] Table 3 Choline dose-dependent effects on pharmacokinetic parameters of paraquat (x±s, n=6)
[0051]
[0052]
[0053] Abbreviations used in the table: t 1 / 2 , half-life; T max , time to reach peak concentration; C max , peak concentration; AUC 0-t , area under the curve; Frel, relative bioavailability.
[0054] Table 4 Effects of different administration times of choline on pharmacokinetic parameters of paraquat. (x±s, n=6)
[0055]
[0056] Abbreviations used in the table: t 1 / 2 , half-life; T max , time to reach peak concentration; C max , peak concentration; AUC 0-t , area under the curve; Frel, relative bioavailability.
[0057] The results in Table 3 show that choline can reduce the blood concentration of paraquat and thus reduce its oral bioavailability at three doses, and show a high degree of concentration dependence. Among them, 500 mg / kg of choline can reduce the maximum blood concentration of paraquat from 40.14±15.57μg / ml to 8.52±1.96μg / ml, and the relative bioavailability from 100% to 28.04%, showing the best inhibition of absorption efficiency. Therefore, 500 mg / kg was selected as the therapeutic dose of choline.
[0058] Figure 2 The effects of different doses of choline on the pharmacokinetics and bioavailability of paraquat (n=6 parallel experiments in each group, NS indicates no significant difference, *p<0.05, **p<0.01). Figure 2 The results showed that under the intervention of different doses of choline, the blood concentration of paraquat in the samples at the sampling time points was significantly lower than that in the non-intervention group, and the corresponding relative bioavailability was significantly reduced, among which the most significant reduction was in the 500 mg / kg dose group (n=6, *p<0.01).
[0059] Table 4 shows the optimization results of choline administration time, which shows that simultaneous administration can reduce the oral bioavailability of paraquat to the greatest extent. Both 30 minutes earlier and 30 minutes later can significantly reduce the oral bioavailability of paraquat. Among them, the 30-minute delay in administration is consistent with the actual clinical treatment administration time, so this time is selected as the subsequent treatment administration time.
[0060] Figure 3 The effects of choline on the pharmacokinetics and bioavailability of paraquat at different administration times (n=6 parallel experiments in each group, NS indicates no significant difference, **p<0.01). Figure 3 The results showed that the maximum blood concentration of paraquat did not change significantly when choline was administered 30 minutes earlier or later, but administration of choline half an hour earlier delayed the maximum blood concentration. Simultaneous administration had the best absorption inhibition effect, which was significantly different from administration in advance (n=6, **p<0.01).
[0061] 4. Effect of choline on the distribution of paraquat in various organs of rats: SD rats aged 8 to 10 weeks and weighing 200±50g were selected and fasted for 24 hours before the experiment. Paraquat was gavaged at a dose of 250mg / kg, and choline was gavaged at a dose of 500mg / kg 30 minutes later. There were 6 parallel experiments in each group. Tissue samples were collected at predetermined time points. Rats were killed by cervical vertebrae and organs such as heart, liver, spleen, lung, and kidney were dissected. They were washed with normal saline, chopped, and homogenized with normal saline twice its mass under ice bath conditions. After homogenization at a speed of 15000rpm for 1 minute, centrifuged at 8000rpm for 10 minutes, 200μL of supernatant was collected, 200μL of 8% perchloric acid was added, vortexed for 30 seconds, and then centrifuged at 8000rpm for 5 minutes. The obtained supernatant was filtered through a 0.45-micron PES membrane and analyzed by high-performance liquid chromatography. The analysis results are shown as follows Figure 4 shown.
[0062] Figure 4 The effect of choline on the paraquat levels accumulated in various organs (n=6 parallel experiments in each group, NS indicates no significant difference, *p<0.05, **p<0.01, ***p<0.005, ****p<0.001). Figure 4 The results showed that oral administration of choline at a dose of 500 mg / kg and delayed for 30 minutes could effectively reduce the accumulation level of paraquat in various organs. The quantitative results at 2 hours showed that the accumulation level of each organ was significantly reduced (**p<0.01). The quantitative results at 24 hours showed that the accumulation level of paraquat in the lung (**p<0.01) and kidney (****p<0.001) was still significantly reduced.
[0063] Example 2
[0064] Application of glucosamine in reducing paraquat accumulation concentration in the lungs: Glucosamine can induce the expression of P-glycoprotein in the lungs of rats after nasal administration, thereby promoting the excretion of paraquat in the lungs and reducing the accumulation concentration in the lungs. The experimental process and results of glucosamine in reducing the accumulation concentration of paraquat in the lungs are as follows:
[0065] 1. Effects of different doses and administration time on up-regulation of P-glycoprotein expression in rat lungs: SD rats aged 8 to 10 weeks and weighing 200 ± 50 g were selected and fasted for 24 hours before the experiment. The glucosamine administration doses were set to 0, 50, and 150 mg / kg, respectively. After the first intranasal drip, glucosamine was dripped into the nose again every 12 hours until the end of the sampling. The sampling time points were set to 24 hours and 72 hours. When sampling, the rats were killed by cervical vertebrae killing method, and the left anterior lobe of the rat lung was taken. 100 mg of tissue was obtained by washing and trimming in PBS, and 1 mL of high-efficiency lysis solution (containing 10 + 10 μL protease and phosphorylase inhibitors) was added. Preliminary homogenization on ice (20000rpm / 0.3min), followed by cell disruption ultrasound (power 50%, on 5s, off 5s, total time 2min), and continued to be placed on ice for lysis for 30 minutes. It can be seen that the system is relatively clear. Centrifuge at 11000rpm for 15 minutes at 4°C and take the supernatant for use. A 10% gel was prepared using the Solebol gel preparation kit. The electrophoresis conditions were 90V for 30 minutes, and the voltage was adjusted to 150V for 60 minutes when the sample ran out of the separation gel. When the bromophenol blue front in the sample tank was about to come out of the gel plate, the electrophoresis was stopped. Transfer the membrane in an ice water bath at 200mA for 1.5 hours and block at room temperature for 20 minutes after completion. After blocking, add the primary antibody for P-glycoprotein (1:1000) and incubate overnight on a shaker in a 4°C refrigerator. After the primary antibody incubation is completed, wash with PBST, and then incubate with the secondary antibody (1:2000) after washing, incubate at room temperature for 1 hour, and wash 5 times, three minutes each time.
[0066] Figure 5 The effects of glucosamine at different doses and administration times on the level of P-glycoprotein in the lungs of rats (n=3 parallel experiments in each group). Figure 5 The results showed that after 24 hours of sampling (i.e., glucosamine was administered intranasally once), there was no significant difference in the expression of P-glycoprotein in the lungs. However, after 5 consecutive intranasal drops at an interval of 12 hours, it was found that glucosamine at a dose of 50 mg / kg could significantly upregulate the expression of P-glycoprotein, while 150 mg / kg of glucosamine did not show an upregulation effect. The above results show that glucosamine significantly upregulates the expression of P-glycoprotein in the lungs of rats in a manner with an optimal dose.
[0067] 2. Study on the accumulation of paraquat in rat lungs at different times: SD rats aged 8 to 10 weeks and weighing 200±50g were selected and fasted for 24 hours before the experiment. Paraquat was gavaged at a dose of 250mg / kg. The sampling time points were set at 2, 12, 24, 48, and 72h. The rats were divided into 5 groups according to the sampling time points, with 6 rats in each group. When sampling, the rats were killed by cervical dislocation, cut along the mid-abdominal line, and both lungs were removed. Use saline to gently wash off the blood on the surface. Weigh and record the weight, add twice the mass of saline, and homogenize under ice bath conditions. Set the speed to 10000r / min and the time to 1min. After homogenization, centrifuge at 8000r / min for 10min, take 200μL of supernatant, add 200μL of 8% perchloric acid, vortex for 30s, centrifuge at 8000r / min for 5min, take the supernatant and filter through 0.45PES membrane. The results of HPLC quantification are as follows: Figure 6 shown.
[0068] Figure 6 Figure 2 is the difference in lung accumulation levels of paraquat at different times (n=6). Figure 6 The results showed that the accumulation of paraquat in the lungs of rats showed a high time dependence, and the lung concentration reached the highest level after 72 hours. Therefore, 72 hours was selected as the sampling time point to verify that glucosamine reduced the accumulation of paraquat in the lungs.
[0069] 3. Effect of different doses of glucosamine on paraquat accumulation in rat lungs: Healthy SD rats were taken and kept in an SPF-grade clean animal room before the experiment. They were fasted but not watered within 24 hours in advance. The paraquat gavage dose was 250 mg / kg, and the glucosamine dose was set to 0, 50, 150, 500, and 1000 mg / kg. Glucosamine was dripped into the nose 12, 24, 36, 48, and 60 hours after gavage with paraquat. The solvent was saline, and the volume of the nose drop was 100 μL. The samples were collected at the preset time point of 72 hours, and the rats were killed by cervical dislocation, cut along the mid-abdominal line, and the lungs were removed. The surface blood was gently washed away with saline, weighed, and the weight was recorded. Add twice the mass of saline and homogenize under ice bath conditions. Set the speed to 10000 r / min and the time to 1 min. After homogenization, centrifuge at 8000r / min for 10min, take 200μL of supernatant, add 200μL of 8% perchloric acid, vortex for 30s, centrifuge at 8000r / min for 5min, take the supernatant and filter through 0.45PES membrane, and analyze by high performance liquid chromatography.
[0070] Figure 7 The effect of different doses of glucosamine administered five times at intervals of 12 hours on the accumulation level of paraquat in the lungs of rats (n=6 parallel experiments in each group, NS indicates no significant difference, *p<0.05). Figure 7The results showed that glucosamine at doses of 150, 500 and 1500 mg / kg could not reduce the lung accumulation level of paraquat, which was basically consistent with the fact that glucosamine induced P-glycoprotein expression in rat lungs at the optimal dose. However, at a dose of 50 mg / kg, glucosamine could significantly reduce the accumulation level (*p<0.05). This result is of great significance. Even if glucosamine is administered from 12 hours after poisoning, it can reduce the accumulation of paraquat in the lungs, which shows that it has great prospects for practical clinical application.
[0071] Example 3
[0072] The combined use of choline and glucosamine can improve the survival rate of paraquat poisoned rats, as shown below:
[0073] After establishing a high-dose acute paraquat poisoning model in rats by gavage of 350 mg / kg of paraquat poisoning, rats were gavaged with choline to reduce blood drug concentrations, and then multiple nasal drops of glucosamine were used to promote lung P-glycoprotein expression and reduce the lung accumulation level of paraquat. The combined use of drugs significantly increased the survival rate of rats from 0% to 80% compared with the administration of either drug alone. The application experimental process and results of the combined use of choline and glucosamine to improve the survival rate of rats poisoned by paraquat are as follows:
[0074] 1. Effect of choline and glucosamine on the survival rate of rats with acute paraquat poisoning: Paraquat was orally administered to rats at a dose of 350 mg / kg to establish a rat model of acute paraquat poisoning. The detoxification effect of oral choline and glucosamine was investigated, and the survival rate of rats within 30 days was used as a reference indicator. SD rats aged 8-18 weeks and weighing about 250±50g were randomly divided into 5 groups (control, paraquat, paraquat-choline, paraquat-glucosamine, paraquat-choline-glucosamine), with 10 rats in each group. The rats in the control group were not given any medication; the rats in the paraquat group were gavaged with 350 mg / kg paraquat, and 30 minutes later, they were gavaged with an equal amount of saline; the rats in the paraquat-choline group were gavaged with 350 mg / kg paraquat, and 30 minutes later, they were gavaged with choline at a dose of 500 mg / kg; the rats in the paraquat+glucosamine group were gavaged with 350 mg / kg paraquat, and 12, 24, 36, 48, and 60 hours later, they were gavaged with 500 mg / kg glucosamine intranasally; the rats in the paraquat+glucosamine group were gavaged with 350 mg / kg paraquat, and 30 minutes later, they were gavaged with choline at a dose of 500 mg / kg, and 12, 24, 36, 48, and 60 hours later, they were gavaged with 50 mg / kg glucosamine intranasally. The rats were observed for 30 consecutive days, and the death time and number of rats in each group were recorded.
[0075] Figure 8The effects of combined and separate administration of choline and glucosamine on the survival rate of rats with acute paraquat poisoning (n=10). Figure 8 The results showed that all rats in the control group survived during the observation period; all rats in the paraquat group died within 6 days, with a survival rate of 0%; the survival rate of rats in the choline intervention group increased to 50% within 30 days; the survival rate of rats in the glucosamine intervention group increased to 40% within 30 days; the combined treatment of choline and glucosamine increased the survival rate of rats to 80% within 30 days. The experimental results show that the combined treatment of choline and glucosamine can significantly improve the survival rate of rats with acute paraquat poisoning.
[0076] Fig. 9 The results of H&E sections of rat lungs after combined administration of choline and glucosamine (n=6), where Ctrl is the control group, PQ+Saline is the paraquat-normal saline group, and PQ+Cho+GlcN is the paraquat-choline-glucosamine group. Fig. 9 The results showed that the lung structure of rats in the control group was intact, with no obvious damage or inflammatory cell infiltration; the rats in the paraquat group lost the typical lung structure, with collapsed and deformed alveoli, congested and edematous lung tissue, and a large number of inflammatory cells infiltrating; the slices of rats in the paraquat-choline-glucosamine group showed alveolar collapse, thickening of the alveolar wall, and inflammatory cell infiltration, but still had intact lung structure, indicating that lung function had not been lost. These results show that the lung damage in the combined drug group was significantly reduced compared with the paraquat group, verifying the effectiveness of the strategy.
[0077] The above experiment shows that cholinergic competitive inhibition significantly inhibits the absorption of paraquat in the small intestine, while glucosamine reduces the accumulation concentration of paraquat in the lungs by inducing the expression of P-glycoprotein in the lungs. On this basis, the two are used in combination, and the strategy is to take 400-600 mg / kg choline orally 30 minutes after oral paraquat poisoning, and then continuously drop glucosamine in the nose at a dose of 40-60 mg / kg at intervals of 12 hours. The experimental results show that the combined drug strategy can significantly increase the survival rate of acutely poisoned rats from 0% to 80%. Similarly, the oral, nasal, and other delivery methods in the above experimental process are modified to atomized inhalation, and the results are consistent with the above results, indicating that choline or glucosamine can be taken orally, nasally, or by other methods such as atomized inhalation in the application of the present invention, and can both improve the survival rate of paraquat poisoners.
[0078] It can be seen that choline can inhibit the absorption of paraquat in the small intestine, and glucosamine can induce the upregulation of the expression of P-glycoprotein in the lungs, thereby reducing the lung accumulation concentration of paraquat. The combination of the two can be better used in the use of drugs to inhibit or treat death caused by paraquat poisoning.
[0079] Since choline materials (including choline or pharmaceutically acceptable salts of choline) are present in the form of choline cations after entering the gastrointestinal tract via oral route, pharmaceutically acceptable salts of choline (any one or more of choline chloride, choline bitartrate, choline bicarbonate, choline hydrochloride or choline sulfate) are also used as antidotes for paraquat, and the effects they can exert are the same as those of choline.
[0080] In summary, the present invention discloses a novel and highly effective paraquat detoxifier: a combined application of choline materials and glucosamine. The application is based on the fact that choline materials can bind to paraquat transporters in the small intestine through competitive inhibition, thereby inhibiting paraquat absorption in the small intestine; glucosamine can promote the pumping out of paraquat in the lungs by inducing up-regulation of P-glycoprotein expression in the lungs, thereby reducing the accumulation concentration of paraquat in the lungs. Based on this, the application method of the present invention is to orally administer choline materials half an hour (adjustable) after oral accidental ingestion of acute paraquat poisoning to reduce the absorption of paraquat in the small intestine. Thereafter, glucosamine is orally administered 5 (adjustable) times at intervals of 12 hours (adjustable) continuously to induce up-regulation of P-glycoprotein expression in the lungs, promote the pumping out of paraquat in the lungs, and thereby reduce the accumulation concentration. Compared with the administration of the two alone, the combined use can significantly increase the survival rate of acute poisoning from 0% to more than 80%.
[0081] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution, which should be included in the scope of the claims of the present invention.
Claims
1. Application of choline materials and glucosamine in the preparation of paraquat antidote, It is characterized in that The choline material is choline or a pharmaceutically acceptable salt of choline.
2. The use according to claim 1, It is characterized in that In the application, the choline material is first delivered to the person to be detoxified, and then glucosamine is delivered to the person to be detoxified as soon as possible within 24 hours.
3. The use according to claim 2, It is characterized in that The delivery is oral, nasal or aerosol inhalation.
4. The use according to claim 2, It is characterized in that The pharmaceutically acceptable salt of choline is any one or more of choline chloride, choline bitartrate, choline bicarbonate, choline hydrochloride or choline sulfate.
5. The use according to claim 1, It is characterized in that In the application, the mass ratio of choline material to the substance to be detoxified is 400-600:1, mg:kg; The mass ratio of the glucosamine to the substance to be detoxified is 40-60:1, mg:kg.
6. A paraquat antidote, It is characterized in that The paraquat detoxifier contains choline materials and glucosamine; The choline material is choline or a pharmaceutically acceptable salt of choline.
7. The paraquat antidote according to claim 6, It is characterized in that The pharmaceutically acceptable salt of choline is any one or more of choline chloride, choline bitartrate, choline bicarbonate, choline hydrochloride or choline sulfate.
